Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists

Archives of Pharmacal Research

Volumn 37, Issue 5, 2014, Pages 588-599

  Zhang, Yu Juan ^a,b   Shen, Liu Lan ^b   Cheon, Hyae Gyeong ^c   Xu, Yong Nan ^a   Jeong, Jin Hyun ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Yonsei University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

GLP 1R; Heterocycles; Small molecule agonists; Structure activity relationships; Synthesis

Indexed keywords

3 [8 CHLORO 6 (TRIFLUOROMETHYL)IMIDAZO[1,2 A]PYRIDIN 2 YL]PHENYL METHANESULFONATE; FUNCTIONAL GROUP; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HETEROCYCLIC COMPOUND; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MOLECULAR LIBRARY; PYRIDINIUM DERIVATIVE;

ARTICLE; BIOLOGICAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR LIBRARY; SYNTHESIS;

ANIMALS; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; PYRIDINIUM COMPOUNDS; RECEPTORS, GLUCAGON; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84901267961     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0253-9     Document Type: Article

References (25)

1. Bower, J. D., and Ramage, G. R. 1955. Heterocyclic systems related to pyrrocoline. Part I. 2: 3a-Diazaindene. Journal of Chemical Society, 2834:2836.
2. Bunders, C.A., J.J. Richards, and C. Melander. 2010. Identification of aryl 2-aminoimidazoles as biofilm inhibitors in Gram-negative bacteria. Bioorganic and Medicinal Chemistry Letters 20: 3797-3800.
3. Buse, J.B., R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron. 2004. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635. (Pubitemid 39441462)
4. Chen, D., J. Liao, N. Li, C. Zhou, Q. Liu, G. Wang, R. Zhang, S. Zhang, L. Lin, K. Chen, X. Xie, F. Nan, A.A. Young, and M.W. Wang. 2007. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proceedings of the National Academy of Sciences of the United States of America 104: 943-948. (Pubitemid 46154716)
5. Cookson, R.C., P.J. Dudfield, and D.I.C. Scopes. 1986. Synthesis of carbocyclic C-nucleoside analogues from 8,9,10-trinorborn-5-en-2-ol. Journal of the Chemical Society, Perkin Transactions 1: 393-398.
6. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
7. Denora, N., V. Laquintana, M.G. Pisu, R. Dore, L. Murru, A. Latrofa, G. Trapani, and E. Sanna. 2008. 2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies. Journal of Medicinal Chemistry 51: 6876-6888.
8. 18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. Journal of Medicinal Chemistry 51: 3700-3712.
9. Giugliano, D., E. Standl, T. Vilsbøll, J. Betteridge, R. Bonadonna, I.W. Campbell, G.-H. Schernthaner, B. Staels, A. Trichopoulou, and E. Farinaro. 2009. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? Acta Diabetologica 46: 173-181.
10. Gong, Y.-D., H.-G. Cheon, T.-H. Lee, and N.-S. Kang. 2010. A novel 3-(8-Chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenyl acetate skeleton and pharmacophore model as glucagon-like peptide 1 receptor agonists. Bulletin of the Korean Chemical Society 31: 3760-3764.
11. Hribal, M.L., and G. Sesti. 2010. Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism 5: 495-505.
12. Kopin, A. S., Beinborn, M. 2004. Methods and compositions for the treatment of metabolic disorders. WO2004103310A2.
13. Kwak, M.K., and H. Ha. 2013. Where are we now in diabetic research? Archives of Pharmacal Research 36: 142-144.
14. Mu, F. 2001. Design, synthesis, and biological evaluation of a series of lavendustin aanalogues that inhibit EGFR and syk tyrosine kinases, as well as tubulin polymerization. Journal of Medicinal Chemistry 44: 441-452. (Pubitemid 32113589)
15. Murphy, K.G., and S.R. Bloom. 2007. Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes? Proceedings of the National Academy of Sciences of the United States of America 104: 689-690. (Pubitemid 46154670)
16. Sennik, D., F. Ahmed, and D. Russell-Jones. 2011. Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism 7: 15-26.
17. Sjöholm, Åke. 2010. Liraglutide therapy for type 2 diabetes: Overcoming unmet needs. Pharmaceuticals 3: 764-781.
18. Stolting, J., Burton, B. 2004. Novel process for the preparation of 2-aminomethylpyridine derivatives. WO 2004096772 A1.
19. Teng, M., M.D. Johnson, C. Thomas, D. Kiel, J.N. Lakis, T. Kercher, S. Aytes, J. Kostrowicki, D. Bhumralkar, L. Truesdale, J. May, U. Sidelman, J.T. Kodra, A.S. Jørgensen, P.H. Olesen, J.C. De Jong, P. Madsen, C. Behrens, I. Pettersson, L.B. Knudsen, J.J. Holst, and J. Lau. 2007. Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorganic and Medicinal Chemistry Letters 17: 5472-5478. (Pubitemid 47391264)
20. Teng, M., Truesdale, L. K., Bhuumralkar, D., Kiel, D., Johnson, M. D., Thomas, C. 2000. Non-peptide GLP-1 agonists. WO2000042026.
21. Toma, T., J. Shimokawa, and T. Fukuyama. 2007. N, N′- ditosylhydrazine: aconvenient reagent for facile synthesis of diazoacetates. Organic Letters 9: 3195-3197.
22. Wang, M. W., Yuan, Y. Y., Zhou, L. 2009. A kind of receptor signaling transolution positive modulators, preparation methods and uses thereof. WO 2009129696A1.
23. Whitehouse, F.W. 1997. Insulin therapy and its shortcomings - the need for new approaches. Diabetic Medicine 14: S5-S8. (Pubitemid 27314278)
24. Yadav, J.S., B.V. Subba Reddy, Y. Gopal Rao, M. Srinivas, and A.V. Narsaiah. 2007. Cu(OTf)2-catalyzed synthesis of imidazo[1,2-a]pyridines from α-diazoketones and 2-aminopyridines. Tetrahedron Letters 48: 7717-7720. (Pubitemid 47451472)
25. Yu, G.J., C.L. Yoo, B. Yang, M.W. Lodewyk, L. Meng, T.T. El-Idreesy, J.C. Fettinger, D.J. Tantillo, A.S. Verkman, and M.J. Kurth. 2008. Potent s-cis-locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. Journal of Medicinal Chemistry 51: 6044-6054.